Faricimab, compared with aflibercept, reduces the risk of epiretinal membrane formation in eyes with diabetic macular edema, research shows.

On July 17, 2025, Harrow, Inc. (“Harrow”), announced an agreement with Samsung Bioepis Co. Ltd. (“Samsung Bioepis”) to acquire the U.S.

The global biosimilars market is driven by less expensive alternatives made possible by the major biologics' patents expiring. The demand for reasonably ...

Lightbridge Corporation ('Lightbridge” or the 'Company”) (Nasdaq: LTBR), an advanced nuclear fuel technology company, will ...

Data showcased in session titled “Spotlight on Drug Delivery” at the Ophthalmology Innovation Source (OIS) Retina 8th Annual Innovation Summit -VLTR-559, a long-acting anti-VEGF therapy, could reduce ...

E yePoint Pharmaceuticals has concluded subject enrolment in the pivotal Phase III programme assessing Duravyu, aimed at ...

Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases ...

LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community – – ...

In this Healio Video Perspective from the Retina World Congress, Ashish Sharma, MBBS, MS, gives an update on aflibercept ...

DAEJEON, South Korea I July 28, 2025 I Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal ...

The commercial license will become effective upon completion of the transition of commercial rights from Biogen back to ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...